PR
Prime Medicine, Inc.
PRME · NASDAQ
$3.12 +0.00% (+$0.00)
1M -4.00%
Market Cap $563.5M
P/E Ratio -
Div. Yield -
ROE 188.27%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 138.36x
P/B 14.16x
P/E N/A
Growth
0 /100
Declining Book val. growth 27.43%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 1,025.61%
Net margin 4,613.11%
Op. margin 4,824.94%
Quality
0 /100
Poor ROIC 86.83%
ROE 188.27%
ROA 75.45%
Debt
33 /100
High Debt/Equity 2.83x
Current ratio 3.05x
Int. coverage N/A
Stability
22 /100
Unstable Beta 2.35x
EPS volatility 40.70%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o PRME
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Allan Reine
Employees
146
Headquarters
Cambridge
Nadchodzące wydarzenia
06 LIS
Earnings
Upcoming earnings report